SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.3200.0%Jan 2 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter H. Hodge who wrote (560)9/30/1997 11:26:00 AM
From: Peter H. Hodge   of 3577
 
Wall Street Journal says runup in Gern price "overdone".
August 27, 1997 12:16 AM

WALL STREET JOURNAL
THE WALL STREET JOURNAL / CALIFORNIA: HEARD IN CALIFORNIA -- SOME FEAR THE RECENT RUN-UP IN GERON SHARES MAY BE OVERDONE

Not new, but I don't think this had been posted before due to the fact that the WSJ just came back online at Daily Stocks. I find it interesting that the two analyists who rate GERN a buy. according to Zacks, are (1) "Scott Sarcane, an analyst at Montgomery Securities in New York, goes so far as to call Geron's work a "scientific home run." (Montgomery was a co-manager of Geron's initial public offering in July 1996 at about $8 a share.)" and (2) "Mr. Jones's technology newsletter, keeps to the long view. He thinks that the stock is a "buy" at $12 or less, but that's strictly for patient investors willing to hang on to their shares at least until 1999".
smartmoney.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News